Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9QM6I)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Retinoic acid receptor beta (RARB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[2]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[3]
PMID27336223-Compound-10	DMYUP6G	N. A.	N. A.	Patented	[1]
PMID27336223-Compound-8	DM460D1	N. A.	N. A.	Patented	[1]
CD666	DMC8X9Y	Discovery agent	N.A.	Investigative	[4]
AGN193109	DMC0YOE	Discovery agent	N.A.	Investigative	[5]
AC55649	DM4JNY9	Discovery agent	N.A.	Investigative	[6]
BMS641	DMRT7G3	Discovery agent	N.A.	Investigative	[7]
AC261066	DMSKE1I	Discovery agent	N.A.	Investigative	[6]
TTNPB	DMSABD0	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Retinoic acid receptor beta (RARB)	TTISP28	RARB_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
2	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
3	Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12.
4	Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83.
5	Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58.
6	Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist. J Med Chem. 2005 Dec 1;48(24):7517-9.
7	Rational design of RAR-selective ligands revealed by RARbeta crystal stucture. EMBO Rep. 2004 Sep;5(9):877-82.
8	9-cis-retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6117-22.